Astellas Pharma Gmbh

Astella Pharma Inc.

Issei Tsukamoto

Chikashi Saitoh

Seijiro Akamatsu

Makoto Takeuchi

Koji Kato

Hiroaki Tanaka

Toru Watanabe

Hiroyuki Koshio

Hiroyuki Moritomo

Noriyuki Kawano

Hideki Kubota

Fukushi Hirayama

Yuji Koga

Jun Takasaki

Hidenori Azami

Takao Okuda

Susumu Watanuki

Daisuke Kaga

Yuta Fukuda

Akio Kakefuda

Yumiko Moritani

Jun Maeda

Hiroyuki Kaizawa

Takanori Koike

Kazuhiro Yokoyama

Ryushi Seo

Kenji Negoro

Yusuke Inagaki

Hajime Takamatsu

Ippei Sato

Yoshinori Okamoto

Tomofumi Takuwa

Taisuke Takahashi

Kazunori Kamijo

Ryutaro Wakayama

Ryo Naito

Masahiro Iwata

Takahiro Kuramochi

Susumu Toda

Kiyoshi Yahiro

Miki Kobayashi

Kazuki Ono

Susumu Igarashi

Hiroyuki Kanoh

Masato Kobori

Thiazole derivatives having pyrazine-2-carbonylamino substituted at the 2-position of the following formula (I): are excellent muscarinic Mreceptor positive allosteric modulators, and are useful for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic Mreceptor. The 2-acylaminothiazole derivatives and salts thereof can be used for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic Mreceptor, for example, voiding dysfunctions such as underactive bladder.

2-acylaminothiazole derivative or salt thereof

[Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.

Sulfonamide compounds or salts thereof

A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.

Sulfonamide compound or salt thereof

A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.

Quinolone derivative or salt thereof

A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof

The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (wherein

Phenylpyridinecarbonylpiperazinederivative

4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof

As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.

Nitrogen-containing heterocyclic compound

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin Vactivity and are useful for a drug for the treatment of central diabetes insipidus and/or nocturia.

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof

Growing community of inventors

Tokyo, Japan

Issei Tsukamoto